The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1615
ISSUE 1615
January 11, 2021
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
January 11, 2021 (Issue: 1615)
The FDA has approved opicapone (Ongentys –
Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an
adjunct to carbidopa/levodopa in adults with Parkinson’s
disease (PD) who experience "off" episodes. It is the
third COMT inhibitor to be approved for this indication;
tolcapone (Tasmar, and generics) and entacapone
(Comtan, and generics) were approved earlier. Opicapone
has been available in Europe since 2016.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
Article code: 1615c
Electronic, downloadable article - $45
Article code: 1615c
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
